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Common and Unique Susceptibility Loci in Graves and Hashimoto
Diseases: Results of Whole-Genome Screening in a Data Set of 102
Multiplex Families
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David A. Greenberg,2,* and Terry F. Davies 1,*
1Division of Endocrinology, Diabetes, and Bone Diseases, Department of Medicine, Mount Sinai School of Medicine, and 2Division
of Statistical Genetics, Columbia University, New York
The autoimmune thyroid diseases (AITDs), comprising Graves disease (GD) and Hashimoto thyroiditis (HT),
develop as a result of a complex interaction between predisposing genes and environmental triggers. Previously,
we identified six loci that showed evidence for linkage with AITD in a data set of 56 multiplex families. The goals
of the present study were to replicate/reject the previously identified loci before fine mapping and sequencing the
candidate genes in these regions. We performed a whole-genome linkage study in an expanded data set of 102
multiplex families with AITD (540 individuals), through use of 400 microsatellite markers. Seven loci showed
evidence for linkage to AITD. Three loci, on chromosomes 6p, 8q, and 10q, showed evidence for linkage with
both GD and HT (maximum multipoint heterogeneity LOD scores [HLOD] 2.0, 3.5, and 4.1, respectively). Three
loci showed evidence for linkage with GD: on 7q (HLOD 2.3), 14q (HLOD 2.1), and 20q (LOD 3.3, in a subset
of the families). One locus on 12q showed evidence of linkage with HT, giving an HLOD of 3.4. Comparison with
the results obtained in the original data set showed that the 20q (GD-2) and 12q (HT-2) loci continued to show
evidence for linkage in the expanded data set; the 6p and 14q loci were located within the same region as the
previously identified 6p and 14q loci (AITD-1 and GD-1, respectively), but the Xq (GD-3) and 13q (HT-1) loci
were not replicated in the expanded data set. These results demonstrated that multiple genes may predispose to
GD and HT and that some may be common to both diseases and some are unique. The loci that continue to show
evidence for linkage in the expanded data set represent serious candidate regions for gene identification.
Introduction
Two distinct but related autoimmune disorders affect the
thyroid gland: Graves disease (GD [MIM #275000]) and
Hashimoto thyroiditis (HT [MIM #140300]). In both
diseases, thyroid-reactive T cells are formed and infiltrate
the thyroid gland. In GD, the majority of the T cells
undergo a Th2 differentiation and activate B cells to
produce TSH receptor (TSHR) antibodies, which stim-
ulate the thyroid and cause clinical hyperthyroidism (re-
viewed by Davies 2000). In contrast, HT is characterized
by Th1 switching of the thyroid-infiltrating T cells,
which induces apoptosis of thyroid follicular cells and
clinical hypothyroidism (reviewed by Weetman 1996).
Both disorders are common, with a prevalence in the
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United States of ∼1% (Jacobson et al. 1997; Hollowell
et al. 2002).
The etiology of the autoimmune thyroid diseases
(AITDs; i.e., GD and HT), and the mechanisms leading
to the dichotomy of GD and HT are unknown. How-
ever, the AITDs are considered complex diseases, caused
by an interaction between susceptibility genes (Tomer
et al. 2002a) and nongenetic factors, such as infection
(Tomer and Davies 1993). This paradigm is based on
epidemiologic evidence demonstrating a genetic predis-
position to AITD, including (1) clustering in families
(Mather et al. 1980), giving a sibling risk ratio (ls) of
110 (Vyse and Todd 1996; Villanueva et al. 2000); (2)
a high concordance rate in MZ twins when compared
with DZ twins (Brix et al. 2000, 2001); (3) the presence
of thyroid autoantibodies, which are markers of sub-
clinical AITD, in as many as 50% of siblings of patients
with AITD (Hall et al. 1972; Burek et al. 1982); and
(4) consistent associations with HLA (Stenszky et al.
1985; Tomer et al. 1997).
In the past few years, several groups, including our
own, have been trying to identify the AITD suscepti-
bility genes by studies of candidate genes and by whole-
genome screening. The candidate-gene studies have
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Table 1
Summary of Loci Reported to Show Evidence for Linkage with AITD
Chromosome
and Locus Phenotype Type of Study Type of Analysisa Results Reference
2:
2q33 (CTLA-4) Thyroid antibodies Whole-genome screening Ped-LOD HLOD 4.2 Tomer et al. 2001
2q33 (CTLA-4) GD Candidate-locus analysis ASP-NPL NPL 3.4 Vaidya et al. 1999
5:
5q31 AITD Whole-genome screening ASP-LOD LOD 3.1 Sakai et al. 2001
6:
6p21 (HLA) GD Candidate-locus analysis ASP-NPL NPL 1.95 Vaidya et al. 1999
6p11 (AITD-1) AITD Whole-genome screening Ped-LOD LOD 2.9 Tomer et al. 1999
6p22-6q14 HT Whole-genome screening One large pedigree LOD 1.52, NPL 7.53 Alkhateeb et al. 2002
8:
8q24 (thyroglobulin) AITD Whole-genome screening ASP-LOD LOD 2.3 Sakai et al. 2001
8q24 (thyroglobulin) AITD Candidate-locus analysis Ped-LOD HLOD 3.5 Tomer et al. 2002c
12:
12q22 (HT-2) HT Whole-genome screening Ped-LOD HLOD 2.3 Tomer et al. 1999
13:
13q32 (HT-1) HT Whole-genome screening Ped-LOD LOD 2.1 Tomer et al. 1999
14:
14q31 GD Whole-genome screening Ped-LOD LOD 2.1 Tomer et al. 1999
18:
18q21 (IDDM-6) GD Candidate-locus analysis ASP-NPL NPL 3.1 Vaidya et al. 2000
20:
20q11 (GD-2) GD Whole-genome screening Ped-LOD LOD 3.5 Tomer et al. 1999
20q11 (GD-2) GD Candidate-locus analysis ASP-NPL NPL 2.01 Pearce et al. 1999
X:
Xq21 (GD-3) GD Whole-genome screening Ped-LOD LOD 2.5 Tomer et al. 1999
Xp11 (IDDMX) GD Candidate-locus analysis ASP-NPL NPL 2.01 Imrie et al. 2001
a Ped p multiplex multigenerational pedigrees; ASP p affected sib pairs.
identified HLA-DR3 (Farid et al. 1980; Zamani et al.
2000) and CTLA-4 (Yanagawa et al. 1995; Tomer et
al. 2001) as putative AITD susceptibility genes, giving
relative risks of 2–4. Only two whole-genome screens
have been published for AITD, one in 56 multiplex
white families (354 individuals) (Tomer et al. 1999) and
another in 123 Japanese sib-pair families (236 individ-
uals) (Sakai et al. 2001). In addition, several limited
studies of chromosomal regions have also been re-
ported. These studies identified several putative AITD
loci (table 1). However, the previous studies have in-
cluded modest data sets and need to be replicated and
confirmed to identify regions likely to harbor AITD sus-
ceptibility genes. We have now almost doubled our
white data set to include 102 multiplex families and
have performed a genome scan on this expanded data
set.
Subjects and Methods
Ascertainment of the Study Families
The project was approved by the Mount Sinai School
of Medicine institutional review board. One hundred
and two families (540 individuals) were analyzed in the
current study (54 from North America, 29 from Italy,
10 from Israel, and 9 from the United Kingdom). All
families enrolled in the study were multiplex for AITD
(i.e., they had more than one affected individual) and/
or multigenerational. Families were ascertained through
a patient with AITD who confirmed having at least one
other first-degree relative with AITD. Although as many
relatives as possible were recruited from each family, the
minimum requirement for participation in the study was
a family consisting of four first-degree relatives (includ-
ing the proband) from two generations. On the average,
our families had 5.3 members.
Clinical assessment.—The AITDs include GD and HT.
GD was diagnosed by (1) documented clinical and bio-
chemical hyperthyroidism requiring treatment, (2) a dif-
fuse goiter, (3) presence of TSHR antibodies, and/or (4)
diffusely increased I-131 uptake in the thyroid gland.
HT was diagnosed by (1) documented clinical and bio-
chemical hypothyroidism requiring thyroid hormone re-
placement and (2) presence of autoantibodies to thyroid
peroxidase (TPO). Antithyroglobulin and anti-TPO an-
tibodies were measured by specific radioimmunoassay
(Kronus). All family members without AITD, whether
thyroid autoantibody–positive or thyroid autoantibody–
negative, were defined for this study as “unaffected.”
For all subjects, phenotype was determined with the cli-
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Table 2
Models Used in Our Analyses
Mode of
Inheritance
AITD
Disease
Frequency
Gene
Frequency Penetrancea
Phenocopy
Rate
Dominant .01 .017 and .006 .3 and .8 0
Recessive .01 .333 and .125 .3 and .8 0
a We computed the LOD score at a .8 penetrance only if a marker
gave a LOD score suggestive of linkage.
nician blinded to the individual’s genotype. Each par-
ticipant was interviewed and examined and gave written
informed consent before participating. All the pertinent
clinical and laboratory data were recorded and stored
in our database. At the time of interview, blood was
collected for DNA purification, as well as for thyroid
function tests and thyroid antibody testing.
PCR Amplification of Microsatellite Markers
DNA was extracted from whole blood through use of
the Puregene kit (Gentra Systems). For the whole-ge-
nome screening, we used the Perkin Elmer microsatellite
panels (version 2.0, a total of 400 markers). Fluores-
cently labeled primers were purchased from Applied
Biosystems, and microsatellite markers were typed as
reported elsewhere (Tomer et al. 1999). In brief, PCRs
were performed in 15-ml reaction volumes containing 50
ng of genomic DNA; 5 pmol of each primer (one of
which was fluorescently labeled); PCR buffer containing
50 mM KCl, 10 mM Tris HCl (pH 8.3), 1.5 mM MgCl2,
and 200 mM each of dATP, dGTP, dTTP, and dCTP; and
1 U of AmpliTaq DNA polymerase (Perkin Elmer, Ap-
plied Biosystems). Reaction mixtures were heated to
94C for 7 min and then cycled 30 times as follows: 30
s at 94C, 30 s at 55C, and 30 s at 72C. The PCR
products were diluted 1:20 in ddH2O and pooled. Two
microliters of the pooled products were mixed with 0.5
ml of the internal size standard and 10 ml of deionized
formamide, denatured, and separated using an ABI 310
genetic analyzer (Applied Biosystems). Allele calling was
performed using Genotyper 2.0 software. The marker
data were then automatically exported to our database
(Ingres Database), where they were integrated with the
already existing phenotype information and prepared for
linkage analysis.
Linkage Analysis
Linkage analysis was performed using maximum like-
lihood-based (LOD score) methods of linkage analysis.
Two-point linkage analysis.—Two-point LOD scores
for the different markers studied were computed using
LIPED software (Ott 1976), assuming both dominant
and recessive models. Population data and our own pre-
vious analyses suggest that a penetrance of 30% is ap-
propriate (Tomer et al. 1999; Brix et al. 2000), but the
actual value of the assumed penetrance does not have a
major effect on the final LOD score (Greenberg 1989).
We considered a LOD score 1.9 in our whole-genome
screen as suggestive evidence for linkage (Lander and
Kruglyak 1995) and a LOD score 3.3 as evidence for
significant linkage, after maximizing the LOD score with
respect to dominant and recessive models (Hodge et al.
1997). If a LOD score was suggestive of linkage, we
then tested at a higher penetrance (80%), since it was
possible that the penetrance of AITD in our families was
higher because of our method of ascertainment (multiple
affected family members) (table 2). For all loci except
two (10q and 12q), this did not result in increased in-
formation. Retesting at 80% penetrance resulted in a
significant increase in the LOD score only for the 10q
and 12q loci (see the “Results” section). All linkage anal-
yses were performed under the assumption of a popu-
lation prevalence of 1% for both diseases (0.5% for GD
and 0.5% for HT), which is based on the disease prev-
alence data in the literature (Tunbridge et al. 1977; Van-
derpump et al. 1995; Hollowell et al. 2002). On the
basis of the assumed disease prevalence, the gene fre-
quency was adjusted according to the model used (dom-
inant or recessive) and the penetrance used, under the
assumption of Hardy-Weinberg equilibrium (table 2).
The phenocopy rate was set at 0; however, previous stud-
ies have shown that the actual value of the assumed
phenocopy rate has little effect on the maximum LOD
score (Durner et al. 1996).
Comparison of the LOD scores obtained in the ex-
panded data set with those obtained in the original data
set.—We previously performed a whole-genome scan in
56 families (“the first data set”) (Tomer et al. 1999),
and the current linkage analysis was performed on an
expanded data set that included an additional 46 fam-
ilies (“the second data set”). To examine what statistical
information has been gained from the addition of the
second data set, we computed the statistic ZtotalZorig for
all of the markers used in the genome screen. This sta-
tistic was computed by calculating the difference be-
tween the maximized maximum LOD score (Greenberg
et al. 1998) obtained for the expanded data set and the
same statistic for the first data set. It should be noted
that the ZtotalZorig statistic is not identical to the LOD
score obtained for the second data set alone, since the
maximum LOD scores for the expanded data set and
the original data set may not occur under the same in-
heritance parameters or at exactly the same location.
Heterogeneity testing and multipoint linkage analy-
sis.—It was possible that genetic heterogeneity existed
in our data set and/or that the simple models used in
the analyses (dominant and recessive) were an incom-
plete description of the complex inheritance of AITD.
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Table 3
Characteristics of the Study Data Set
Group No. %
Families: 102 100
Families with GD 34 33
Families with GD with GOa proband 11 11
Families with HT 30 30
Mixed families (GDHT) 38 37
Individuals: 540 100
Affected individuals: 250 46b
Female 208 83c
Male 42 17c
Unaffected individuals: 290 54b
Female 138 48d
Male 152 52d
a GO p Graves ophthalmopathy.
b Percentage of total individuals.
c Percentage of affected individuals.
d Percentage of unaffected individuals.
Thus, we did a multipoint linkage analysis, under the
assumption of heterogeneity, for all 23 chromosomes.
The marker positions were according to the Genome
Database and Ge´ne´thon chromosomal genetic maps.
The order of the markers and recombination fractions
in the Genome Database and Ge´ne´thon maps were ver-
ified in our data set. Multipoint LOD scores and mul-
tipoint heterogeneity LOD scores (HLODs) were com-
puted by the Genehunter program (Kruglyak et al.
1996), using all the markers on each chromosome. Mul-
tipoint linkage analysis yields the maximum marker in-
formation for the area of interest. Using Genehunter, we
set the inheritance parameters to the values that gave
the maximum LOD scores in the two-point analyses. As
we did in the two-point linkage analysis, we assumed a
population prevalence of 1% for AITD and adjusted the
gene frequency accordingly.
Predivided sample test.—To try to resolve the hetero-
geneity in our data set, we applied the predivided sample
test (Morton 1956; Ott 1999). In this test, the data set
is divided into different groups on the basis of clinical
or demographic criteria, and the LOD scores obtained
in each subset are compared. If the difference in the LOD
scores for the two subsets of families is statistically sig-
nificant, then it suggests that the two groups are genet-
ically different from one another at the tested locus
(Morton 1956; Ott 1999). Since our data set consisted
of a large Italian subgroup that could have been different
from the rest of our families owing to genetic and/or
subtle ascertainment differences, we subdivided our data
set into Italian and non-Italian families and applied the
predivided sample test.
Affectedness and disease models.—The AITDs in-
clude GD and HT. It was not clear whether the suscep-
tibility genes for these two disorders were unique or
common to both diseases. Indeed, both disorders can
occur in the same family. In our data set, 37% of the
families included first-degree relatives with GD and HT.
Therefore, we analyzed the data using three models:
1. Affectedness status AITD: all patients with AITD
were considered as affected (loci identified using this
model would confer susceptibility for both GD and
HT).
2. Affectedness status GD: only patients with GD were
considered as affected (under this model, patients
with HT were considered as unaffected even if they
had relatives with GD).
3. Affectedness status HT: only patients with HT were
considered as affected (under this model, patients
with GD were considered as unaffected even if they
had relatives with HT).
Analysis for linkage with GD in which HT was consid-
ered unknown and analysis for linkage with HT in which
GD was considered unknown were also performed, but,
in all cases, the changes in the LOD scores were insig-
nificant. Family members with thyroid autoantibodies
alone were classified as “unaffected.” In addition, we
computed the LOD scores, under the assumption of het-
erogeneity (HLOD), using Genehunter (Kruglyak et al.
1996).
Results
Characteristics of the Study Sample
Table 3 shows the clinical characteristics of the 102
families studied. Thirty-four (33%) had only GD-af-
fected members, 30 (30%) had only HT-affected mem-
bers, and 38 (37%) had both GD- and HT-affected first-
degree relatives. Of the 250 affected individuals, 208
(83.2%) were female, and the affected female:male (F:
M) ratio, 5:1, was in accordance with that reported in
the literature (Volpe 1985). Thirty-five percent of the
clinically and biochemically unaffected family members
had thyroid antibodies, similar to the incidence reported
in previous studies (Burek et al. 1982; Aho et al. 1983).
Whole-Genome Screening for the AITD Genes
Two-point LOD scores.—For mapping the AITD genes
(i.e., genes causing both GD and HT), individuals with
either GD or HT were considered affected. Figure 1A
shows the results of whole-genome screening for AITD
loci. Three loci, on chromosomes 6p, 8q, and 10q, gave
LOD scores 12.0. At the 6p locus, the maximum two-
point LOD score was 2.1 for marker D6S422 (34 cM),
obtained for the recessive model, at a penetrance of 30%
and a recombination fraction (v) of 0.2 (fig. 1A; table
4). At the 8q locus, the maximum two-point LOD score
was 2.9 for marker D8S284 (136.4 cM), obtained for
the recessive model, at a penetrance of 30% and a v of
0.1 (fig. 1A; table 4). The maximum two-point LOD
Figure 1 A, Whole-genome analysis for loci linked with both GD and HT (AITD). The X-axis shows the relative marker positions on
each chromosome, and the Y-axis shows the two-point LOD score obtained for each marker on every chromosome. Three loci, on chromosomes
6p, 8q, and 10q (marked by asterisks [*]), gave two-point LOD scores 12. B, The differences between the two-point LOD scores obtained in
the expanded data set and those obtained in the original data set. The X-axis shows the relative marker positions on each chromosome, and
the Y-axis shows ZtotalZorig for each marker. Two loci, on chromosomes 8q and 10q, showed a notable increase in LOD scores. One marker
on 2q also showed an increase in LOD score, but the Ztotal at this locus remained !2.
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Table 4
Two-Point and Multipoint LOD Scores at Loci Showing Evidence
for Linkage with AITD (LOD 12)
Phenotype
and Marker
Name
Chromosomal
Location
Two-Point
LOD v
Multipoint
HLOD a
AITD:
D6S422 6p 2.1 .2 2.0 .59
D8S284 8q 2.9 .1 3.5 .6
D10S537 10q 3.6 .2 4.1 .5
GD:
D7S502 7q 2.2 .1 2.3 .7
D14S258 14q 2.1 .2 2.1 .32
D20S195 20q 1.2a .1 1.5a .38
HT:
D12S351 12q 2.6 .2 3.4 .5
a When we excluded the Italian subset, the two-point LOD score
was 2.6 and the multipoint LOD score was 3.3, with no heterogeneity.
Table 5
Comparison of the Multipoint HLOD Scores Obtained in the First
Data Set and in the Expanded Data Set
LOCUS MARKER
MARKER
POSITIONa
(cM)
HLOD SCORE IN
First Data
Set ( )np 56
Expanded Data
Set ( )np 102
GD-2 D20S195 47.8 3.5 3.3b
GD-3 DXS8020 101.2 2.5 .5
HT-1 D13S173 103.6 2.1 .9
HT-2 D12S346 102.0 2.3 3.4
7q D7S502 81.2 1.4 2.3
8q D8S284 136.4 1.8 3.5
10q D10S537 93.3 1.8 4.1
a The distance of the marker from the p-terminal end of the
chromosome.
b This multipoint LOD score was obtained for the white non-Italian
families ( ) without assuming heterogeneity.np 73
score at the 10q locus was 2.7 for marker D10S537 (93.3
cM), under the assumption of a recessive model, at a
penetrance of 30% and a v of 0.2. At a penetrance of
80%, the LOD score for marker D10S537 increased to
3.6 (fig. 1A; table 4). To determine the increase in in-
formation gained from the addition of the second data
set, we computed the ZtotalZorig for the 400 markers
used for whole-genome screening. Figure 1B shows the
results of the differences in the two-point LOD scores
between the extended and the original data sets
(ZtotalZorig). An increase in LOD scores was seen at the
8q and 10q loci. The multipoint HLOD scores also in-
creased from 1.8 to 3.5 and 4.1 at 8q and 10q, respec-
tively (table 5). One marker on 2q also showed an in-
crease in the LOD score, but the Ztotal at this locus
remained !2.
Heterogeneity testing and multipoint analysis.—Multi-
point analyses using Genehunter showed significant
HLOD scores at the same three loci on chromosomes
6p, 8q, and 10q that were identified by the two-point
analysis (fig. 2). The maximum multipoint LOD scores
at the 6p, 8q, and 10q loci under the assumption of
homogeneity were 0.2, 2.2, and 3.1, respectively.
However, under the assumption of heterogeneity, the
maximum multipoint HLOD scores were 2.0 for the 6p
locus, 3.5 for the 8q locus, and 4.1 for the 10q locus
(fig. 2; table 4). Thus, our data demonstrated strong
evidence for heterogeneity at the 10q locus, whereas it
is unclear whether there is genetic heterogeneity at the
6p and 8q loci. However, heterogeneity cannot be quan-
tified by these methods, since the a statistic has been
shown to be an inaccurate measure of the percentage of
families with linkage (Vieland et al. 2001; Pal and Green-
berg 2002).
Subset analysis by phenotype.—We examined subsets
of our families (defined by clinical phenotype—i.e., GD
or HT) to see whether they contributed most of the
positive LOD scores at the three identified AITD loci.
We therefore tested these loci separately in our GD, HT,
and mixed families (table 6). Subset analysis for the 10q
locus showed that all three subsets contributed equally
to the total LOD score. However, for the 6p and 8q loci,
only the families with HT or GD gave positive LOD
scores, whereas the mixed families gave negative LOD
scores (table 6). This may imply that the mixed families
form a subset of our families that is influenced by dif-
ferent loci than the families with GD or HT. Alterna-
tively, the mixed families may show intrafamilial het-
erogeneity at the 6p and the 8q loci.
Whole-Genome Screening for GD Genes
For screening the unique GD genes (i.e., genes causing
GD but not HT), we defined as “affected” only indi-
viduals with GD (therefore, the families with HT were
excluded from analysis by definition, only the families
with GD and mixed families were screened, and only
the GD-affected family members were treated as af-
fected). Two loci gave two-point LOD scores 12.0, on
chromosomes 7q and 14q. The maximum two-point
LOD score at the 7q locus was 2.1 for marker D7S502
(81.2 cM), obtained for the recessive model, at 0.3 pen-
etrance and a v of 0.1 (table 4). The maximum two-
point LOD score at the 14q locus was 2.1 for marker
D14S258 (71.6 cM), obtained for the dominant model,
at 0.3 penetrance and a v of 0.2 (table 4). The previously
identified GD-2 (20q) locus (Tomer et al. 1998) showed
a maximum two-point LOD score of 1.2 for marker
D20S195 (47.8 cM), obtained for the recessive model,
at 0.3 penetrance and a v of 0.1 (table 4). Since our data
set consisted of a large subset of Italian families, we
reanalyzed this locus with the Italian families excluded
( ). The GD-2 (20q) locus gave a LOD score ofnp 29
2.6 without an assumption of heterogeneity when we
divided the families into subsets on the basis of the coun-
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Figure 2 Multipoint analysis for chromosomes 6, 8, and 10. The X-axis shows the relative marker position in centimorgans, and the Y-
axis shows the multipoint HLOD score. The maximum multipoint HLOD scores were 2.0 for the 6p locus, 3.5 for the 8q locus, and 4.1 for
the 10q locus.
try of origin and excluded Italian families from the anal-
ysis (Tomer et al. 2002b). The multipoint LOD score at
GD-2 (20q) was 3.3 when we excluded the Italian fam-
ilies (table 4). Application of the predivided-sample test
(Morton 1956; Ott 1996) showed that there was statis-
tically significant evidence for linkage heterogeneity at
20q in the Italian families versus the non-Italian white
families, with the Italian families showing evidence
against linkage at this locus ( ; 1 df; )2x p 9.2 P ! .01
(Tomer et al. 2002b).
Whole Genome Screening for HT Genes
For screening the unique HT genes (i.e., genes causing
HT but not GD), we defined as “affected” only indi-
viduals with HT (therefore, the families with GD were
excluded from analysis by definition, only the families
with HT and mixed families were used, and only the
HT-affected family members were classified as affected).
One locus showed evidence for linkage only with HT
on 12q. The maximum two-point LOD score was 1.9
at marker D12S346 (102 cM), under the assumption of
a recessive model, at a penetrance of 0.3 and a v of 0.2.
At a penetrance of 80%, the LOD score increased to
2.6. The maximum multipoint HLOD (recessive model,
80% penetrance) was 3.4 (table 4).
Comparison of the Whole-Genome Screen Results
Obtained in the First Data Set with Those Obtained
in the Expanded Data Set
Our initial whole-genome screen was performed in 56
families, and the expanded data set included an addi-
tional 46 families (a total of 102 families). Comparison
of the results obtained for the expanded data set with
the results obtained from the original data set showed
that, at four of six sites, there is continued evidence for
linkage (tables 5 and 7). Two loci (HT-2 and GD-2)
continued to show strong evidence of linkage in the ex-
panded data set, with LOD scores 13 (table 5). For two
additional loci (AITD-1 and GD-1), we obtained peak
LOD scores of 12 ∼20–30 cM away from the original
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Table 6
Two Point LOD Scores Obtained for the Families with
GD Only, HT Only, and Mixed Families
LOCUS
LOD SCORE IN
Families
with GD
( )np 34
Families
with HT
( )np 30
Mixed
Families
( )np 38
All Families
( )Np 102
6p 1.0 1.9 .8 2.1
8q 1.5 1.8 .4 2.9
10q 1.0 1.5 1.1 3.6
Table 7
Comparison of the Multipoint HLOD Scores Obtained in
the First Data Set and in the Expanded Data Set for the
AITD-1 and GD-1 Loci
LOCUS
AND
MARKER
MARKER
POSITIONa
(cM)
HLOD SCORE IN
First Data
Set ( )np 56
Expanded Data
Set ( )np 102
AITD-1:
D6S257 62.8 2.9 1.5
D6S422 34.0 2.0 2.0
GD-1:
D14S81 91.7 2.5 1.2
D14S258 71.6 1.0 2.1
a The distance of the marker from the p-terminal end of
the chromosome.
locus (table 7), and, at present, it is unclear whether they
represent the same loci or different loci. In contrast, for
two additional loci that gave positive LOD scores in the
first data set (GD-3 and HT-1), the LOD scores became
negative in the expanded data set; thus, these loci could
not be confirmed (table 5).
Discussion
The mechanisms underlying the genetic predisposition
to AITD are unknown. Although a hereditary compo-
nent in the pathogenesis of these diseases has long been
recognized, the inheritance appears to be complex, in-
volving multiple genes with variable penetrances. More-
over, the genetic relationship between GD and HT is not
known, and, even within GD and HT, there exists sig-
nificant phenotypic heterogeneity. Previous linkage stud-
ies by our own group and others have identified several
loci as potential genetic regions harboring AITD sus-
ceptibility genes (table 1). However, previous studies em-
ployed only small numbers of families and/or individ-
uals. We report here the largest whole-genome linkage
study performed in AITD to date. Our data demon-
strated significant LOD scores (12) at seven loci: three
loci (6p, 8q, and 10q) showed evidence for linkage with
both GD and HT, three loci (7q, 14q, and 20q) showed
evidence for linkage with GD, and one locus (12q)
showed evidence for linkage with HT.
Comparison of the results obtained for this expanded
data set with the results obtained for the original data
set showed that the addition of the second data set re-
sulted in a notable increase in statistical information
(fig. 1B; table 5). Our first genome screen, performed
in 56 families, showed evidence for linkage at six sites:
6p (AITD-1) showed evidence for linkage with both GD
and HT; 14q (GD-1), 20q (GD-2), and Xq (GD-3)
showed evidence for linkage with GD; and 13q (HT-1)
and 12q (HT-2) showed evidence for linkage with HT.
The results obtained in the expanded data set showed
that four of six loci show continued evidence for linkage
(tables 5 and 7), whereas two loci, GD-3 and HT-1,
gave negative LOD scores in the expanded data set and,
thus, could not be confirmed (table 5). The other four
loci continued to show evidence for linkage in the ex-
panded data set. Two loci (HT-2 and GD-2) continued
to show strong evidence for linkage in the expanded
data set (table 5). For HT-2 (12q) the maximum two-
point LOD score increased from 2.3 in the original data
set to 3.4 in the expanded data set. For GD-2 (20q),
the LOD scores remained 12.0 in the expanded data
set, but only when we excluded the Italian families from
the analysis. Since the original data set had few Italian
families and the expanded data set consisted of ∼30%
Italian families, this effect was noticeable only in the
expanded data set. We have now identified a putative
susceptibility gene at the GD-2 locus region, the CD-
40 gene (Tomer et al. 2002b). Since the second data set
was “enriched” in Italian families, we did similar subset
analysis (excluding the Italian families) at the other loci
we identified, but in none of them except GD-2 did we
resolve the heterogeneity by dividing the families into
subsets on the basis of geographic origin (data not
shown).
For two additional loci (AITD-1 and GD-1), we ob-
tained peak LOD scores of 2 ∼20–30 cM away from
the original locus. Marker D6S257 (AITD-1) gave a
maximum multipoint LOD score of 2.9 in the original
data set and 1.5 in the expanded data set (table 7).
However, in the expanded data set, there was a peak
LOD score of 2.0 at marker D6S422 located ∼30 cM
telomeric to D6S257 (table 7). Although this is a large
distance, it may represent the same locus (AITD-1), and
the differences in map positions may be due to inac-
curacies of the current genetic maps and/or due to ge-
netic heterogeneity. A similar phenomenon was ob-
served for the GD-1 locus. Marker D14S81 (GD-1) gave
a maximum multipoint LOD score of 2.5 in the original
data set and 1.2 in the expanded data set (table 7).
However, in the expanded data set, marker D14S258,
located 30 cM centromeric to D14S81, gave a maxi-
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mum multipoint LOD score of 2.1 and, again, may
represent the same locus. Thus, of the six loci originally
identified, two showed increased evidence for linkage
(GD-2 and HT-2), two showed significant LOD scores
in the same chromosomal regions as the original loci
(AITD-1 and GD-1), and two were not replicated (GD-
3 and HT-1). In addition, for three loci that gave low
positive LOD scores (1.0–2.0) in the original data set
(D8S284, D10S537, and D7S502), the LOD scores in-
creased to significance levels (12.0) in the expanded data
set (table 5). As mentioned above, our analyses were
performed assuming two modes of inheritance (domi-
nant and recessive) and two penetrances (30% and
80%). Greenberg et al. (1998) have shown that maxi-
mizing LOD scores over modes of inheritance, as we
did, increases the power of the analysis significantly.
However, because of the multiple testing, the recom-
mendation is to subtract 0.3 from the obtained LOD
score (Hodge et al. 1997). In our case, that would have
resulted in a LOD score of 1.7 for the 6p locus, 3.2 for
the 8q locus, 3.8 for the 10q locus, 2.0 for the 7q locus,
1.8 for the 14q locus, 3.0 for the 20q locus, and 3.1
for the 12q locus (see table 4). Thus, at all loci except
6p and 14q, the LOD scores remained above the cutoffs
suggested by Lander and Kruglyak (1995). The signif-
icance of the 6p and 14q loci will have to be determined
by studying additional data sets.
Comparison of our results with those obtained in the
genome screen performed by Sakai et al. (2001) dem-
onstrated evidence for linkage, at the 8q locus in their
Japanese data set, that was replicated in our data set;
however, the 5q locus that gave a LOD score of 13.0
in the Japanese data set did not show evidence for link-
age in our data set (two-point LOD 0.54). The AITD-
1 (6p) locus is within a broad region that showed evi-
dence for linkage with HT in a genome scan performed
in a large family in which vitiligo and HT occurred in
numerous individuals (Alkhateeb et al. 2002). Another
locus, GD-2 (20q), showed evidence for linkage in a
U.K. data set (nonparametric linkage [NPL] score 2.0)
(Pearce et al. 1999). Thus, three of the seven loci we
identified showed evidence for linkage in independent
data sets.
The AITDs are unique; even though their clinical
manifestations are different, they share common im-
munopathogenetic mechanisms. Therefore, two hy-
potheses have been proposed to explain the etiology of
the AITDs. According to one hypothesis, GD and HT
share common genetic susceptibility, whereas differing
environmental encounters and immunological modu-
lating factors determine the final phenotype (Phillips et
al. 1990). The second hypothesis proposes that, even
though GD and HT are autoimmune diseases of the
same organ (thyroid), they represent separate disease
entities caused by distinct genes. Our study shed light
on the genetic relationship between GD and HT. Three
loci (6p, 8q, and 10q) showed evidence for linkage with
both GD and HT, implying that there is significant
shared genetic susceptibility to GD and HT. This is also
suggested by the fact that more than a third of the
families have both diseases (table 3). Moreover, subset
analysis showed that these three loci showed positive
LOD scores in both the families with GD and the fam-
ilies with HT, again supporting a strong shared genetic
susceptibility for GD and HT (table 6). However, the
mixed families gave positive LOD scores only for the
10q locus and not for the 6p and 8q loci (table 6). This
may imply that, in the mixed families, the development
of AITD is influenced by unique loci not contributing
to AITD in the families with GD or HT. Alternatively,
the mixed families may represent intrafamilial hetero-
geneity. Therefore, the shared genetic susceptibility to
GD and HT may be different in the mixed families than
in the families with GD or HT. Preliminary data suggest
that the shared genetic susceptibility for GD and HT
may involve both immune regulatory genes (e.g., CTLA-
4 [Vaidya et al. 1999; Tomer et al. 2001]) and thyroid-
specific genes (Tomer et al. 2002c). However, we also
found loci that were unique to GD and HT, implying
that genetic factors also contribute to the distinct GD
and HT phenotypes. Since all loci showed evidence for
linkage with heterogeneity, the relative weights of the
shared susceptibility loci and the unique loci for GD
and HT cannot be assessed until the heterogeneity is
resolved.
Some of the loci we have identified harbor interesting
positional candidate genes. These include both immune
regulatory genes and thyroid-specific genes. The 6p
(AITD-1) locus harbors the SOX-4 gene, an immune
modulator (Schilham et al. 1997). This locus is also
close to a major immune regulatory gene cluster, the
human leukocyte antigen (HLA) complex. However,
previous studies by our group (Barbesino et al. 1998;
Ban et al. 2002) and others (Bode et al. 1973; Hawkins
et al. 1985; Shields et al. 1994) have shown strong ev-
idence against linkage of the HLA locus to AITD. These
data suggest that the 6p (AITD-1) locus is distinct from
the HLA gene cluster. It is interesting that an insulin-
dependent diabetes locus (IDDM-15 [MIM #601666])
(Delepine et al. 1997) and a systemic lupus erythema-
tosus (SLE) locus (Gaffney et al. 1998) were identified
in the same location as AITD-1, and this may imply
that a general autoimmunity susceptibility gene is lo-
cated in this region. Indeed, AITD is known to be as-
sociated with insulin-dependent diabetes (Gray et al.
1983; Kordonouri et al. 2002) and with SLE (Miller et
al. 1987; Weetman and Walport 1987) in the same in-
dividuals and to cluster together in families. The 8q
locus harbors the thyroglobulin gene, and our prelim-
inary data suggest that the thyroglobulin gene may be
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the AITD susceptibility gene in this region (Tomer et al.
2002c). In addition, the 20q locus (GD-2) harbors the
CD40 gene, and we have preliminary data showing that
an SNP in the Kozak sequence of CD40 is associated
with GD (Tomer et al. 2002b).
Complex diseases are likely to be caused by the in-
teraction of several genes, and their combined effects
may differ in different individuals and families (Vyse
and Todd 1996). In type I diabetes mellitus, at least 12
susceptibility loci have been identified by several groups
(Davies et al. 1994; Hashimoto et al. 1994; Luo et al.
1995, 1996); in AITD, we identified seven loci, and
additional loci were identified by others (table 1). It is
most likely that these loci interact and that their inter-
actions may influence disease phenotype and severity
(Tomer et al. 1999). Indeed, locus interactions were re-
ported in type 2 diabetes (Cox et al. 1999), in murine
lupus (Vyse et al. 1997), and in epilepsy (Durner et al.
2001). The molecular basis for the interactions between
susceptibility genes in complex diseases is unknown.
These interactions could represent the cumulative effect
of increased statistical risk, or, alternatively, there may
be molecular interactions between the susceptibility
genes or their products that ultimately determine disease
phenotype. Another unresolved question is that of
which loci harbor major genes (i.e., genes that are nec-
essary for developing the disease) and which loci harbor
minor modulating genes (i.e., genes that alter the effects
of the major genes but are not necessary for disease
development). To better understand these effects, we
need to identify the susceptibility genes for AITD and
the underlying molecular mechanisms by which they
allow the induction of thyroid autoimmunity.
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